Martin Shkreli, known for his controversial past in the pharmaceutical industry, is facing legal action for allegedly breaching a court-imposed lifetime ban that prohibits him from engaging in pharmaceutical trading. The Federal Trade Commission (FTC) and six state attorneys general have requested that a federal judge hold Shkreli in contempt for purportedly trading stocks and flaunting his market activities on social media.
Shkreli, 43, garnered notoriety in 2015 when his company, Turing Pharmaceuticals, raised the price of the essential medication Daraprim from $17.50 to $750 per pill. Following a conviction for securities fraud in 2017, he faced a nearly $65 million judgment and was given a lifetime ban from the industry in February 2022 after serving a seven-year prison sentence.
After his release, Shkreli is said to have resumed trading in pharmaceutical stocks, livestreaming his activities and even boasting of substantial profits. Court documents indicate that he traded shares in over 60 pharmaceutical firms since July 2022, including major companies like Pfizer and Moderna. Claims have emerged that he leveraged social media to manipulate stock prices of small biotech firms, resulting in significant financial gains.
Authorities are demanding a full accounting of Shkreli’s trading activities and financial penalties equivalent to his profits from these transactions, along with potential incarceration if he continues to disregard the court’s orders. Additionally, Shkreli’s significant others are also implicated in facilitating his trading activities, further complicating the case against him. His history of regulatory violations and public antics have drawn heightened scrutiny and concern from federal and state officials.
Why this story matters:
- Highlights ongoing issues of accountability in the pharmaceutical industry.
Key takeaway:
- Shkreli continues to engage in trading despite a lifetime ban, prompting actions from regulators.
Opposing viewpoint:
- Some argue that regulatory scrutiny may be overreaching given Shkreli’s rights to engagement in financial markets post-incarceration.
